Suppr超能文献

P16免疫染色模式作为早期子宫颈癌淋巴结转移和复发的预测标志物

P16-immunostaining pattern as a predictive marker of lymph node metastasis and recurrence in early uterine cervical cancer.

作者信息

Yamazaki Tatsuo, Tomita Shigeki, Ichikawa Kazuhito, Ono Yuko, Inaba Fujiyuki, Fukasawa Ichio, Imai Yasuo, Imura Johji, Fukui Hirokazu, Fujimori Takahiro, Inaba Noriyuki

机构信息

Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, Shimotsuga, Tochigi, Japan.

出版信息

Pathobiology. 2006;73(4):176-82. doi: 10.1159/000096018.

Abstract

OBJECTIVES

We investigated the relationship between P16-immunostaining patterns and clinicopathological factors in early uterine cervix cancers and assessed whether P16-immunostaining patterns predict the prognosis of the patients with early uterine cervix cancers.

METHODS

Twenty-nine early squamous cell carcinoma (SCC) specimens of the uterus were examined using immunohistochemistry for P16 expression. The P16-immunostaining pattern was classified into two groups: the homogeneous type and the heterogeneous type. P16-immunostaining patterns were evaluated in different parts of the carcinoma in situ (CIS): the center of the tumor and the front interface of the infiltrating tumor.

RESULTS

All specimens were of the homogeneous type in CIS. The P16-immunostaining pattern was significantly of the heterogeneous type in the front interface of the infiltrating tumor with lymphatic invasion, vascular invasion, lymph node metastasis, and recurrence. Regarding the P16-immunostaining patterns in the front interface of the infiltrating tumor, the patients with the heterogeneous type showed a significantly worse prognosis than the patients with the homogeneous type.

CONCLUSIONS

The prognosis of patients with early uterine cervical SCC may be predicted by evaluating the P16-immunostaining pattern in the front interface of the infiltrating tumor.

摘要

目的

我们研究了早期子宫颈癌中P16免疫染色模式与临床病理因素之间的关系,并评估P16免疫染色模式是否能预测早期子宫颈癌患者的预后。

方法

采用免疫组织化学方法检测29例早期子宫鳞状细胞癌(SCC)标本中P16的表达。P16免疫染色模式分为两组:均匀型和异质型。在原位癌(CIS)的不同部位评估P16免疫染色模式:肿瘤中心和浸润性肿瘤的前沿界面。

结果

所有标本在CIS中均为均匀型。在伴有淋巴浸润、血管浸润、淋巴结转移和复发的浸润性肿瘤前沿界面,P16免疫染色模式显著为异质型。关于浸润性肿瘤前沿界面的P16免疫染色模式,异质型患者的预后明显比均匀型患者差。

结论

通过评估浸润性肿瘤前沿界面的P16免疫染色模式,可能预测早期子宫颈SCC患者的预后。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验